Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 12,500 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 12,500 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.97, for a total transaction of $349,625.00. Following the completion of the transaction, the chief financial officer owned 129,855 shares in the company, valued at approximately $3,632,044.35. This trade represents a 8.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Wednesday, July 8th, Ivan Hyep sold 28,000 shares of Bicara Therapeutics stock. The shares were sold at an average price of $28.85, for a total value of $807,800.00.
• On Thursday, May 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.42, for a total transaction of $187,864.00.

Bicara Therapeutics Stock Performance

Shares of NASDAQ:BCAX opened at $24.63 on Thursday. The company has a market cap of $1.62 billion, a PE ratio of -7.95 and a beta of -0.75. Bicara Therapeutics Inc. has a 52 week low of $10.30 and a 52 week high of $30.99. The firm has a 50 day simple moving average of $26.00 and a 200 day simple moving average of $21.74.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting the consensus estimate of ($0.82). On average, equities analysts predict that Bicara Therapeutics Inc. will post -3.42 earnings per share for the current year.

Trending Headlines about Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara reported second-quarter adjusted earnings of -$0.82 per share, in line with expectations, while investors focused on continued progress in its pivotal cancer trial. Enrollment remains on track for 2026, an important milestone for the company’s lead program. Bicara Therapeutics stock gains as pivotal trial enrollment advances
• Positive Sentiment: Analyst sentiment improved after the results. BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, implying substantial potential upside based on the company’s clinical outlook. Other analysts also increased their forecasts after the quarterly report. Bicara Therapeutics analysts raise forecasts
• Positive Sentiment: Wedbush said the company’s cancer study remains on track for 2026 enrollment, reinforcing expectations that Bicara could reach significant clinical catalysts over the coming months. Bicara Therapeutics cancer study remains on track
• Neutral Sentiment: Analyst views remain mixed. Wells Fargo raised its target from $16 to $23 but retained an Equal Weight rating, placing its target below the stock’s recent trading level. Bicara also announced strategic leadership transitions as it moves into its next phase of execution. Wells Fargo price-target update
• Negative Sentiment: CEO Claire Mazumdar, COO Ryan Cohlhepp and CFO Ivan Hyep collectively sold 41,250 shares for approximately $1.15 million. The transactions were conducted under pre-arranged Rule 10b5-1 plans, and each executive retained a sizable position, reducing—but not eliminating—the negative signal from insider selling. Bicara insider transaction filings

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its position in Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics during the 4th quarter worth $45,000. Larson Financial Group LLC increased its stake in shares of Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after purchasing an additional 4,585 shares in the last quarter.

Wall Street Analyst Weigh In

BCAX has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. Wells Fargo & Company increased their price target on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Guggenheim assumed coverage on shares of Bicara Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $42.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. Finally, Morgan Stanley upped their price objective on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.73.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.